Brain tumors comprise a large spectrum of malignancies often associated with severe neurological symptoms and fatal outcome. Tumors are characterized by histology or immunohistochemistry, which yields information about tumor type, origin, state and prognosis. This however, cannot predict the underlying biochemical and genetics events that are important for patient outcome. Molecular biomarkers are required to extend and refine prognostic and predictive information, providing more individualized and optimized treatment options. In our research we are applying several robust approaches, with extra high resolution and coverage to deeply characteriz of different types of brain tumors. The specific approaches includes exome-seq, RNA-seq, ChIP-seq and array-cgh.
This provides important insights into the molecular mechanisms controlling tumor development and allow for the detection of novel candidate genes that may serve as biomarkers to improve disease stratification as well as targets for future therapies. Progress in genetic testing is needed to allow the use of personal therapy, which seeks to deal with each patient depending on their individual characteristics. Results from our projects will contribute to this development.